Could “triple-therapy” considered as a novel-optimal treatment model for acute bipolar depression? A prospective real-world research in China

Yaling Zhou,Xu Zhang,Ruhan A,Yuexin Chen,Xueli Sun,Ruhan A.

DOI: https://doi.org/10.1016/j.jpsychires.2020.09.017

IF: 5.25

2020-12-01

Journal of Psychiatric Research

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Results of researches of bipolar depression treatment are inconsistent and to our knowledge, no study has previously revealed an optimal treatment model for bipolar depression in the real-world through a prospective way.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>To find out an optimal treatment model for bipolar depression in the real-world by evaluating the effect of different treatment models: monotherapy, double-therapy and triple-therapy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Design</h3><p>and Intervention: This 12 or 16-week, multi-center, real-world clinical study was conducted at 15 study sites (inpatient or outpatient department) in West China and a total of 573 patients completed the follow-up. During the study weeks, all researchers could choose a most proper treatment model freely basing on the evaluation of patient's symptoms and complete the follow-up according to the procedure.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Main outcomes and measures</h3><p>The primary outcomes were baseline-to–endpoint change in Montgomery-Asberg Depression Rating Scale(MADRS) total score and the constituent ratio of effects. Total score change in Young Mania Rating Scale(YMRS) and Clinical Global Impression(CGI) from baseline to endpoint, treatment-emergent mania rate and severe adverse events rate were used as secondary outcomes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>During all study weeks, all the 3 groups showed a statistically significant improvement in MARDS, YMRS and CGI (<em>P</em>&lt;0.001),but the triple-therapy group showed much more effective in significant response and response rates at endpoint than double-therapy group and monotherapy group(<em>P</em>&lt;0.001) with lower treatment-emergent mania rates(<em>P</em>=0.001). At week 4, mean scores of MARDS in triple-therapy group are statistically significant lower than monotherapy group(<em>P</em>=0.013) and at the endpoint, mean scores of MARDS in triple-therapy group are statistically significant lower than both double-therapy and monotherapy groups(<em>P</em>=0.011). The severe adverse events rates are rare in all the 3 groups at week 4 and endpoint, and the rate of dry mouth in triple-therapy group at week 4 is statistically significant lower than the other 2 groups(<em>P</em>=0.002).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Triple-therapy is more effective in treating bipolar depression than double-therapy and monotherapy model with a lower risk of developing manic symptoms.</p>

psychiatry